ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Salidroside reduces neuropathology in Alzheimer's disease models by targeting NRF2/SIRT3 pathway

Yao, Yuyuan; Ren, Zhichu; Yang, Ruihan; Mei, Yilan; Dai, Yuying; Cheng, Qian; Xu, Chong; Xu, Xiaogang; Wang, Sanying; Kim, Kyoung Mi; Noh, Ji Heon; Zhu, Jian; Zhao, Ningwei; Liu, Yong U.; Mao, Genxiang*; Sima, Jian*1
Cell and Bioscience2022-11-4DOI: 10.1186/s13578-022-00918-z
15被引4阅读
引用收藏
分享

摘要

Background Neurite dystrophy is a pathologic hallmark of Alzheimer's disease (AD). However, drug discovery targeting neurite protection in AD remains largely unexplored. Methods A beta-induced neurite and mitochondrial damage assays were used to evaluate A beta toxicity and the neuroprotective efficacy of a natural compound salidroside (SAL). The 5xFAD transgenic mouse model of AD was used to study the neuroprotective function of SAL. To verify the direct target of SAL, we used surface plasmon resonance and cellular thermal shift assays to analyze the drug-protein interaction. Results SAL ameliorates A beta-mediated neurite damage in cell culture. We further reveal that SAL represses mitochondrial damage in neurites by promoting mitophagy and maintaining mitochondrial homeostasis, dependent on an NAD-dependent deacetylase SIRT3. In AD mice, SAL protects neurite morphology, mitigates A beta pathology, and improves cognitive function, which are all SIRT3-dependent. Notably, SAL directly binds to transcription factor NRF2, inhibits its degradation by blocking its interaction with KEAP1 ubiquitin ligase, and then advances NRF2-mediated SIRT3 transcription. Conclusions Overall, we demonstrate that SAL, a potential anti-aging drug candidate, attenuates AD pathology by targeting NRF2/SIRT3 pathway for mitochondrial and neurite protection. Drug discovery strategies focusing on SAL may thus provide promising therapeutics for AD.

学科与关键词

关键词
Alzheimer's diseaseMitochondrial protectionSALSIRT3NRF2
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cell and Bioscience
发表日期
2022-11-04
卷期
第 12 卷, 第 1 期
页码
180
DOI
10.1186/s13578-022-00918-z
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82173804, 81771520]; High-Level Talents Start-up Funding of China Pharmaceutical University [3150120042]

作者

  • Y

    Yao, Yuyuan (第一作者)

    china pharmaceut univ

  • R

    Ren, Zhichu

    china pharmaceut univ

查看全部 16 位作者收起作者
  • Y

    Yang, Ruihan

    china pharmaceut univ

  • M

    Mei, Yilan

    china pharmaceut univ

  • D

    Dai, Yuying

    china pharmaceut univ

  • C

    Cheng, Qian

    china pharmaceut univ

  • X

    Xu, Chong

    china pharmaceut univ

  • X

    Xu, Xiaogang

    zhejiang hosp

  • W

    Wang, Sanying

    zhejiang hosp

  • K

    Kim, Kyoung Mi

  • N

    Noh, Ji Heon

  • Z

    Zhu, Jian

  • Z

    Zhao, Ningwei

  • L

    Liu, Yong U.

    1

  • M

    Mao, Genxiang (通讯)

    zhejiang hosp

  • S

    Sima, Jian (通讯)

    china pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417